Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials

Abstract Metastatic colorectal cancer (mCRC) continues to show poor outcomes, with many patients exhausting effective standard‐of‐care therapy. To explore the current landscape of clinical trials for mCRC, we reviewed over 600 clinical trials that are currently ongoing for mCRC patients. Immunotherapeutic agents form approximately 39% (includes monoclonal antibodies, viruses, vaccines, and immunomodulators) of all agents and targeted therapy forms 45% (tyrosine kinase inhibitors, epigenetic modulators, and others) of all agents being investigated for mCRC.